Rheumatoid Arthritis

The Pharmacy Times® Rheumatoid Arthritis resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
Inflammation caused by rheumatoid arthritis may increase the risk of type 2 diabetes.

 
[[thumbnail_alt_text]]
The FDA has approved tofacitinib for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis. 
 
[[thumbnail_alt_text]]
A recent study found that patients on immunosuppressive therapy for common skin and rheumatic diseases, such as psoriasis and rheumatoid arthritis, are not at an increased risk for contracting COVID-19.
[[thumbnail_alt_text]]
Recent studies have analyzed how individuals with autoimmune conditions prescribed specialty medications may be affected by the COVID-19 pandemic.
[[thumbnail_alt_text]]
The Mediterranean diet has shown efficacy in preventing several noncommunicable diseases. 
 
[[thumbnail_alt_text]]
The new studies found that for some patients, the use of steroid medications to reduce inflammation slighly increased the likelihood of needing hospital care for COVID-19.
 
[[thumbnail_alt_text]]
Extended glucocorticoid use can cause complications such as cardiovascular disorders, infections, and osteoporosis, according to a new study.  

 
[[thumbnail_alt_text]]
What characteristics of RA treatments possibly connect to COVID-19 treatment?
 
[[thumbnail_alt_text]]
The American College of Rheumatology addresses the prior authorization requirement for some prescription medications, highlighting the significant burden this creates for patients and rheumatology professionals.
[[thumbnail_alt_text]]
The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs. 
[[thumbnail_alt_text]]
Officials with the FDA have approved Amgen’s infliximab-axxq (Avsola), a new biosimiliar to infliximab (Remicade).
[[thumbnail_alt_text]]
It is currently uncertain to what extent interleukin inhibitors may increase the risk of serious infections and cancer in patients being treated for rheumatic diseases.